查詢結果分析
來源資料
相關文獻
- Safety and Efficacy of the Platelet Glycoprotein IIb/IIIa Inhibitor Abciximab in Chinese Patients Undergoing High-Risk Angioplasty
- Adrenergic Effects on Left Ventricular Functions in Coronary Patients after Successful Coronary Angioplasty: An Assessment with Radionuclide Ventriculography
- Clinical Characteristics and Coronary Risk Factors of Patients with Low Concentrations of Serum Low-Density Lipoprotein Cholesterol and Total Cholesterol
- The First Multicenter Coronary Stenting Registration in Taiwan
- 心臟病患對心臟復健工作的認知與實施需求之探討
- 心肌灌注掃描
- 執行心臟復健運動對一位冠狀動脈疾病患者活動耐力之成效
- 冠狀動脈疾病之侵襲性療法--PTCA與CABG的比較
- 以運動放射核種血管造影術及運動鉈-210心肌灌注造影術評估冠狀動脈疾病之比較
- 冠狀動脈疾病之致病機轉
頁籤選單縮合
題 名 | Safety and Efficacy of the Platelet Glycoprotein IIb/IIIa Inhibitor Abciximab in Chinese Patients Undergoing High-Risk Angioplasty=血小板醣蛋白IIb/IIIa接受體拮抗劑abciximab對接受冠狀動脈成形術具有高危險性患者之療效 |
---|---|
作 者 | 陳嬰華; 陳肇文; 吳道正; 丁予安; 王石補; 張茂松; | 書刊名 | 中華醫學雜誌 |
卷 期 | 63:1 2000.01[民89.01] |
頁 次 | 頁8-15 |
分類號 | 415.3161 |
關鍵詞 | 冠狀動脈成形術; 冠狀動脈疾病; 血小板凝集抑制劑; Angioplasty; Coronary disease; Platelet inhibition inhibitor; |
語 文 | 英文(English) |
中文摘要 | 背景:血小板在冠狀動脈成形術所造成之併發症中扮演著相當重要的角色。過去血小板抑制劑以aspirin為主,但事實上aspirin的抗血小板作用並不強。近年,研制出一類新的血小板抑制劑(即血小板醣蛋白IIb/IIIa接受體拮抗體),它可抑制血小板凝集之最後管道。本研究旨在探討血小板醣蛋白IIb/IIIa接受體拮抗劑abciximab對接受冠狀動脈成形術具有高危險性患者之療效。 方法:本研究為一前瞻性、雙盲設計。42位需接受冠狀動脈成形術之患者參與了研究,他們均具有高危險性之臨床特徵,包括不穩定性心絞痛或高危險性冠狀動脈病變。在接受冠狀動脈成形術時他們被隨機分成兩組,分別接受安慰劑或abciximab靜脈快速注射及其後12小時連續靜注。所有患者均接受低劑量、根據體重調整之肝素治療。在術後30天比較兩組併發症(包括死亡、急性心肌梗塞、需緊急接受冠狀動脈繞道術、再次冠狀動脈成形術、血管支架置放術或置放主動脈內氣球幫浦等)之發生率。 結果:與安慰劑組比較,abciximab能減少冠狀動脈成形術後急性心肌梗塞之發生率(由15%降至0%,p=0.099)。而兩組間之出血併發症及需要輸血的比率均無顯著差異。 結論:對接受冠狀動脈成形術具有高危險性之患者來說,使用血小板醣蛋白IIb/IIIa接受體拮抗劑abciximab能降低術後急性心肌梗塞的發生率。此藥併用低劑量之肝素及提早移除髓鞘,可降低出血併發症的發生率。 |
英文摘要 | Background: Platelets are believed to play a role in the ischemic complications of coronary angioplasty, such as abrupt closure of coronary vessels during or soon after the procedure. Accordingly, we evaluated the effect of a chimeric monoclonal antibody abciximab, directed against the platelet glycoprotein IIb/IIIa receptor, in patients undergoing angioplasty who were at high risk for ischemic complications. This receptor is the final common pathway for platelet aggregation. Methods: In a prospective, double-blind trial, we randomly assigned 42 patients to receive a bolus and an infusion of placebo or a bolus and an infusion of abciximab. Low-dose, weight-adjusted heparin (initial dose of 70 U/kg of body weight) was used in both groups. Patients underwent coronary angioplasty for high-risk clinical situations involving unstable angina or high-risk coronary morphologic characteristics. The primary study endpoint consisted of any of the following: death, nonfatal myocardial infarction, unplanned surgical revascularization, unplanned repeat percutaneous procedure, unplanned implantation of a coronary stent, or insertion of an intra-aortic balloon pump for refractory ischemia within 30 days of randomization. Results: Compared with placebo, the abciximab resulted in a trend toward reduction in periprocedural myocardial infarction from 15% to 0%, although the differences were not statistically significant (p=0.099). There were no significant differences between the two groups in the risk of major and minor bleeding and the need for blood transfusion. Conclusions: Inhibition of platelet glycoprotein IIb/IIIa receptor with abciximab, together with low-dose, weight-adjusted heparin, had a favorable trend toward the reduction of periprocedural myocardial infarction in patients undergoing high-risk angioplasty, without increasing the risk of hemorrhage. |
本系統中英文摘要資訊取自各篇刊載內容。